Targeted coating with antigenic peptide renders tumor cells susceptible to CD8 + T Cell-mediated killing

Molecular Therapy

Volumn 21, Issue 3, 2013, Pages 542-553

  Kang, Tae Heung ^a   Ma, Barbara ^a   Wang, Connie ^a   Wu, T C ^a,b   Hung, Chien Fu ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; EPITOPE; FURIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESOTHELIN SINGLE CHAIN VARIABLE FRAGMENT ANTIBODY ARGINYLVALYLLYSYLARGININE SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE ARGINYLVALYLLYSYLARGININE IMMUNOGLOBULIN G2A FC FRAGMENT; MESOTHELIN SINGLE CHAIN VARIABLE FRAGMENT ANTIBODY IMMUNOGLOBULIN G2A FC FRAGMENT; MESOTHELIN SINGLE CHAIN VARIABLE FRAGMENT ANTIBODY SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE IMMUNOGLOBULIN G2A FC FRAGMENT; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T CELL MEDIATED KILLING; CELL KILLING; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84875231220     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.233     Document Type: Article

References (29)

1. Sznol, M and Holmlund, J (1997). Antigen-specific agents in development. Semin Oncol 24: 173-186.
2. Scholler, N, Fu, N, Yang, Y, Ye, Z, Goodman, GE, Hellström, KE et al. (1999). Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 96: 11531-11536.
3. Hassan, R, Bera, T and Pastan, I (2004). Mesothelin: a new target for immunotherapy. Clin Cancer Res 10(12 Pt 1): 3937-3942.
4. Coppola, JM, Bhojani, MS, Ross, BD and Rehemtulla, A (2008). A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia 10: 363-370.
5. Page, RE, Klein-Szanto, AJ, Litwin, S, Nicolas, E, Al-Jumaily, R, Alexander, P et al. (2007). Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol 29: 289-299.
6. Mercapide, J, Lopez De Cicco, R, Bassi, DE, Castresana, JS, Thomas, G and Klein-Szanto, AJ (2002). Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness. Clin Cancer Res 8: 1740-1746.
7. Bassi, DE, Mahloogi, H, Al-Saleem, L, Lopez De Cicco, R, Ridge, JA and Klein-Szanto, AJ (2001). Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog 31: 224-232.
8. Cheng, M, Watson, PH, Paterson, JA, Seidah, N, Chrétien, M and Shiu, RP (1997). Pro-protein convertase gene expression in human breast cancer. Int J Cancer 71: 966-971.
9. Schalken, JA, Roebroek, AJ, Oomen, PP, Wagenaar, SS, Debruyne, FM, Bloemers, HP et al. (1987). Fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas. J Clin Invest 80: 1545-1549.
10. Thomas, G (2002). Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 3: 753-766.
11. Currier, JR, Kuta, EG, Turk, E, Earhart, LB, Loomis-Price, L, Janetzki, S et al. (2002). A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260: 157-172.
12. Lu, J, Higashimoto, Y, Appella, E and Celis, E (2004). Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol 172: 4575-4582.
13. Chowdhury, PS, Viner, JL, Beers, R and Pastan, I (1998). Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci USA 95: 669-674.
14. Lev, A, Noy, R, Oved, K, Novak, H, Segal, D, Walden, P et al. (2004). Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo. Proc Natl Acad Sci USA 101: 9051-9056.
15. Kersemaekers, AM, Fleuren, GJ, Kenter, GG, Van den Broek, LJ, Uljee, SM, Hermans, J et al. (1999). Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 5: 577-586.
16. Maurizi, M, Almadori, G, Ferrandina, G, Distefano, M, Romanini, ME, Cadoni, G et al. (1996). Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74: 1253-1257.
17. Inada, S, Koto, T, Futami, K, Arima, S and Iwashita, A (1999). Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today 29: 493-503.
18. Fischer-Colbrie, J, Witt, A, Heinzl, H, Speiser, P, Czerwenka, K, Sevelda, P et al. (1997). EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 17(1B): 613-619.
19. Mellon, K, Wright, C, Kelly, P, Horne, CH and Neal, DE (1995). Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 153(3 Pt 2): 919-925.
20. Normanno, N, De Luca, A, Bianco, C, Strizzi, L, Mancino, M, Maiello, MR et al. (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16.
21. Nicholson, RI, Gee, JM and Harper, ME (2001). EGFR and cancer prognosis. Eur J Cancer 37 Suppl 4: S9-15.
22. Ross, JS and Fletcher, JA (1998). The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16: 413-428.
23. Chang, CL, Wu, TC and Hung, CF (2007). Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther 14: 1189-1198.
24. Hung, CF, Calizo, R, Tsai, YC, He, L and Wu, TC (2007). A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine 25: 127-135.
25. Peng, S, Monie, A, Kang, TH, Hung, CF, Roden, R and Wu, TC (2010). Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. Gene Ther 17: 1453-1464.
26. Gu, M, Rappaport, J and Leppla, SH (1995). Furin is important but not essential for the proteolytic maturation of gp160 of HIV-1. FEBS Lett 365: 95-97.
27. Wang, TL, Ling, M, Shih, IM, Pham, T, Pai, SI, Lu, Z et al. (2000). Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 7: 726-733.
28. Conejo-Garcia, JR, Benencia, F, Courreges, MC, Kang, E, Mohamed-Hadley, A, Buckanovich, RJ et al. (2004). Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 10: 950-958.
29. Roby, KF, Taylor, CC, Sweetwood, JP, Cheng, Y, Pace, JL, Tawfik, O et al. (2000). Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21: 585-591.